Clinical pharmacological studies on centpropazine--a new antidepressant compound.
Artigo
em Inglês
| IMSEAR
| ID: sea-20119
ABSTRACT
Single oral doses of 10 to 160 mg centpropazine, a new antidepressant (synthesized by CDRI, Lucknow, India) were administered to groups of 4-5 male volunteers, each dose being interspersed with placebo in a double blind, non-crossover study by random distribution. The drug was well tolerated. Drowsiness, heaviness, weakness and/or headache were reported only at doses of 120 mg and above. No adverse effect was noted in various laboratory tests, ECG or vital parameters. In a multiple dose study, volunteers received 40 or 80 mg centpropazine daily for 4 wk. Mild restlessness and insomnia were observed in some subjects receiving 80 mg dose. In this study also no effect was observed in various laboratory tests, ECG or vital parameters.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Piperazinas
/
Idoso
/
Humanos
/
Masculino
/
Distribuição Aleatória
/
Método Duplo-Cego
/
Adolescente
/
Adulto
/
Relação Dose-Resposta a Droga
/
Avaliação de Medicamentos
Tipo de estudo:
Ensaio Clínico Controlado
Idioma:
Inglês
Ano de publicação:
1989
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS